Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
NCT ID: NCT06987045
Last Updated: 2025-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2025-08-01
2027-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people.
Anyone with a prostate can get prostate cancer. The prostate remains after genital (lower) surgery. The hormones and surgeries that trans women and non-binary people might have can lower the PSA. We do not have good data on the normal PSA levels are for this group
TransPRIDE is a research study that will help us find the normal levels of PSA in trans women and non-binary people with prostates.
Researchers will ask 500 trans women and non-binary people with prostates to take part. They will need to be aged 40 or over. They will need to be on hormones or have had lower surgery. They will be called after 6 months to recheck their health. If a person has a high PSA, they may be sent for more tests.
Knowing the normal PSA level for trans women and non-binary people will help doctors to find and treat their prostate cancer more quickly.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
NCT00898274
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
NCT00373035
Prostate Biomarker Study
NCT00574899
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
NCT03234556
Test Semiquantitative Prostate Specific Antigen (PSA)
NCT00853710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
40-49 year olds
No interventions assigned to this group
50-59 year olds
No interventions assigned to this group
60-79 year olds
No interventions assigned to this group
70+ year olds
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Transgender or non-binary (identify with a gender other than the one assigned at birth)
* With a prostate
* Fulfills at least one of the following 3 criteria with regards to gender-affirming medical care:
* Taking oestradiol for at least the last 3 months
* Taking anti-androgens for at least the last 3 months
* Ever had bilateral orchidectomy
* Eligible for National Health Service (NHS) treatment
Exclusion Criteria
* History of prostate surgery at any time
* History of prostate radiotherapy at any time
* History of benign prostatic hypertrophy (enlarged prostate) at any time
* Vaginoplasty within 12 months
* Orchidectomy or vulvoplasty within three months
* Sexually Transmitted Infection (STI) within 6 weeks of blood sample
* Active urinary infection or within 6 weeks of blood sample
* Prostatitis within 6 weeks of blood sample
* Urological intervention (e.g. prostate biopsy) within 6 weeks of blood sample
* Unwilling to give consent
* Lacking capacity to give consent
* In the secure estate
40 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen Mary University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
336982
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.